Journal article
PET/CT and renal pathology: a blind spot for radiologists? Part 2--lymphoma, leukemia, and metastatic disease.
Abstract
OBJECTIVE: PET/CT with (18)F-FDG is a powerful tool to evaluate patients with hematologic malignancy or to assess the burden of metastatic disease from solid tumors. Metabolically active renal pathology associated with lymphoma, leukemia, or metastatic disease can be missed without close attention to both the PET and CT portions of the study because of physiologic FDG excretion in the kidneys. This article illustrates the appearance of tracer …
Authors
Zukotynski K; Lewis A; O???Regan K; Jacene H; Sakellis C; Almodovar S; Israel D
Journal
American Journal of Roentgenology, Vol. 199, No. 2, pp. w168–w174
Publisher
American Roentgen Ray Society
Publication Date
August 2012
DOI
10.2214/ajr.11.7923
ISSN
0361-803X